Japanese Submission
18 Juillet 2008 - 8:00AM
UK Regulatory
RNS Number : 3440Z
Arthro Kinetics plc
18 July 2008
Japanese Submission for CaReS� Clinical Studies
FRIDAY, 18th July 2008 * Arthro Kinetics plc (AIM: AKI) (*Arthro Kinetics* or the *Company*), the orthopedics company dedicated to
regenerating joint mobility and spinal disc function announces that PolarisRx, Arthro Kinetics* joint venture partner has successfully
completed and submitted its Kakunin Shinsei to the Japanese Ministry of Health and Welfare seeking approval to begin clinical studies for
CaRaS� in Japan.
In addition, Arthro Kinetics* joint venture partner in China, Arthro-ANDA Tinajin Biologics Technology Co. (*AATBT*), has received a grant
from the Special Funds for Technology Innovation of Tianjin Municipal Government, for a sum of RMB 8 million (EUR740,000). These monies will
be used by AATBT to advance CaReS� into clinical studies in China in the second half of 2008.
Jason Loveridge, CEO of Arthro Kinetics comments; *These are both important events for AKI signaling the advancement of our autologous
chrondrocyte implant - CaReS� - into clinical studies in important markets for the Company and the continuing success of our joint ventures
in Japan & China.*
CONTACTS
Arthro Kinetics Plc Tel: +49 (0)711 305 110 70
Jason Loveridge, Chief Executive Officer
Doug Quinn, Chief Financial Officer
Nomura Code Securities Limited Tel: +44 (0)207 776 1200
Richard Potts
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCGUUGCMUPRGAM
Arthro Kinetics (LSE:AKI)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Arthro Kinetics (LSE:AKI)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Arthro Kinetics (London Stock Exchange): 0 recent articles
Plus d'articles sur Arthro Kinetics Plc